The Mark Foundation for Cancer Research

Gallbladder and bile duct cancers remain stubbornly fatal, in part because they are often only discovered once the disease has progressed. We're committed to changing that. In partnership with the American Association for Cancer Research and The Lustgarten Foundation, we're funding an Early Detection Award to accelerate research and improve outcomes for these and other difficult-to-diagnose cancers. Letters of intent are due March 10! Learn more: https://lnkd.in/guey_Wue #GallbladderCancerAwarenessMonth #BileDuctCancerAwarenessMonth #EarlyDetection

New breakthrough in the fight against #chordoma! In Nature Magazine Communications, researchers funded by The Mark Foundation & the Chordoma Foundation map the structure of brachyury, a transcription factor that drives tumor growth, and point to potential drug-binding sites. https://lnkd.in/e8ppQHwp The paper, authored by David Drewry at UNC Eshelman School of Pharmacy, Opher Gileadi at the University of Oxford, and Paul Workman at The Institute of Cancer Research, challenges the long-held belief that brachcyury was undruggable, offering new hope for treatment. It also holds personal meaning for Workman:? https://lnkd.in/eZPZdNSj #CancerResearch #ResearchFunding

? Reminder! ? We are currently accepting proposals for an ASPIRE Award focused on intrinsically disordered proteins and cancer. Letters of intent are due Feb 28—submit yours soon! https://lnkd.in/e_jTpYZw #CancerResearch #ResearchFunding

Which trends in cancer research will shape progress in 2025 and beyond? Mark Foundation CEO Ryan Schoenfeld shares his thoughts in Labiotech.eu's roundup. https://lnkd.in/emUiQTHt #CancerResearch #Immunology

How can we ensure cancer research thrives despite current uncertainties? Mark Foundation CEO Ryan Schoenfeld and Board Chair Ray DuBois share their perspective in The Cancer Letter: https://lnkd.in/eZfw-hdu #CancerResearch #ResearchFunding

?? Two new funding opportunities!?? Early Detection Award: In partnership with the American Association for Cancer Research and The Lustgarten Foundation, we are seeking proposals focused on accelerating the development of effective new approaches to the early detection of cancer. Letters of intent are due March 10. Learn more: https://lnkd.in/guey_Wue ASPIRE Award: We are also currently accepting letters of intent for an ASPIRE Award focused on intrinsically disordered proteins in cancer. Proposals are due February 28. Learn more: https://lnkd.in/e_jTpYZw Please share these opportunities with your networks! #CancerResearch #ResearchFunding

??Announcing The Mark Foundation 2025 Emerging Leader Award winners! ?? These 5 outstanding early-career scientists will receive a total of $3.75 million to pursue projects with the potential to transform cancer research. We can’t wait to see what they achieve! Liron Bar-Peled at Mass General Cancer Center will use his ELA to develop "molecular staples," a new class of drugs designed to disrupt oncogenic fusion proteins, which form when two genes abnormally join together and can drive many different types of cancers. Kai Kessenbrock at UC Irvine will investigate the hypothesis that inherited BRCA1 mutations cause widespread alterations in breast tissue, including changes to the immune system, which may promote the initiation of breast cancer. Ansuman Satpathy at Stanford University will engineer T cell states with enhanced anti-cancer activity using synthetic transcription factors to modulate gene expression and advanced machine learning tools. Mara Sherman at Memorial Sloan Kettering Cancer Center will seek to uncover how different types of cancer-associated fibroblast cells drive tumor growth and resistance to therapy in pancreatic cancers and work to identify new strategies for treatment. Daniel Wahl at Michigan Medicine will examine how glioblastoma cells siphon nutrients from surrounding non-cancerous cells in the brain to fuel tumor growth and treatment resistance, information that will be used to develop improved therapies. Congratulations to all our awardees! ?? ?? ??

“We’re not just funding research; we’re building a global network and pushing the boundaries of what’s possible in cancer research.” - Mark Foundation CEO Ryan Schoenfeld Read Gevorg Tamamyan's interview with Schoenfeld in OncoDaily to learn how we’re accelerating discovery in the fight against cancer. https://lnkd.in/e33bd2NH #CancerResearch #ResearchFunding

New Johnson & Johnson data shows that pairing the bispecific antibody amivantamab with?lazertinib significantly extends the survival of patients with EGFR-mutated non-small cell lung cancer. Last October, Mark Foundation CEO Ryan Schoenfeld told BioSpace why he’s bullish on bispecifics: https://lnkd.in/erZQ9QW7 #NSCLC #immunotherapy

Congratulations to Mark Foundation Scientific Advisory Committee member Scott Armstrong MD, PhD! He’s been named one of Boston Business Journal's 2025 Innovators in Healthcare for his work leading research and pediatric oncology at Dana-Farber Cancer Institute. ???? https://lnkd.in/eQXUMqNH